Clinical Trials
33 trialsTumor HI
Rezolute
Multicenter Trial of ESK981 in Patients With Select Solid Tumors
University of Michigan Rogel Cancer Center
Testing Cabozantinib in Patients With Advanced Pancreatic Neuroendocrine and Carcinoid Tumors
National Cancer Institute (NCI)
STELLAR-311
Exelixis
Study of RYZ401 in Subjects With Solid Tumors Expressing SSTRs.
RayzeBio, Inc.
ACTION-1
RayzeBio, Inc.
Gene Modified Immune Cells After Conditioning Regimen for the Treatment of Stage IIIC or IV Melanoma or Metastatic Solid Tumors
Stanford University
Oral Cryotherapy Plus Acupressure and Acupuncture Versus Oral Cryotherapy for Decreasing Chemotherapy-Induced Peripheral Neuropathy From Oxaliplatin-Based Chemotherapy in Patients With Gastrointestinal Cancer
University of Washington
Abemaciclib in Treating Patients With Advanced, Refractory, and Unresectable Digestive System Neuroendocrine Tumors
University of Washington
Study of CVM-1118 for Patients With Advanced Neuroendocrine Tumors
TaiRx, Inc.
Intermediate-Size Cohort EAP for Ersodetug in Patients With Inadequately Controlled Hypoglycemia Related to a Tumor
Rezolute
A Safety Study of 212Pb-VMT-alpha-NET in Patients With Neuroendocrine Tumors
University of Iowa
Patients With High-grade Pancreatic Neuroendocrine Tumors
National Cancer Center, Korea
Genetic Bases of Neuroendocrine Neoplasms in Mexican Patients
Universidad Nacional Autonoma de Mexico
Trial of Nab-sirolimus in Patients With Well-differentiated Neuroendocrine Tumors (NETs) of the Gastrointestinal Tract, Lung, or Pancreas Who Have Not Received Prior Treatment With mTOR Inhibitors
Aadi Bioscience, Inc.
EVENET
AC Camargo Cancer Center
BANN
University Medical Center Groningen
Nonfunctioning Small (≤2 cm) Neuroendocrine Pancreatic Incidentaloma
Société Française d'Endoscopie Digestive
RGS-GEP-NET
European Institute of Oncology
AMG 706 and Octreotide in Treating Patients With Low-Grade Neuroendocrine Tumors
Eastern Cooperative Oncology Group
Combination Chemotherapy and Bevacizumab in Treating Patients With Advanced Neuroendocrine Tumors
University of California, San Francisco
TNE-P-Ki
Institut Paoli-Calmettes
Procaspase Activating Compound-1 (PAC-1) in the Treatment of Advanced Malignancies - Component 1
Vanquish Oncology, Inc.
Phase II Study of Ibrutinib in Advanced Carcinoid and Pancreatic Neuroendocrine Tumors
H. Lee Moffitt Cancer Center and Research Institute
AMG 479 in Advanced Carcinoid and Pancreatic Neuroendocrine Tumors
Dana-Farber Cancer Institute
COOPERATE-2
Novartis
Pasireotide in Combination With RAD001 in Patients With Advanced Neuroendocrine Tumors
Dana-Farber Cancer Institute
68Ga
Vanderbilt-Ingram Cancer Center
Recombinant Anti-tumor and Anti-virus Protein for Injection to Treat Advanced Neuroendocrine Tumors
The Affiliated Hospital of the Chinese Academy of Military Medical Sciences
NET
Assistance Publique - Hôpitaux de Paris
Sorafenib in Combination With RAD001 in Patients With Advanced Neuroendocrine Tumors
Dana-Farber Cancer Institute
68Ga-DOTATATE PET Scan Imaging in Patients With Neuroendocrine Tumors
Ochsner Health System
Phase II Study of Sunitinib Malate Following Hepatic Artery Embolization
H. Lee Moffitt Cancer Center and Research Institute